U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476118) titled 'A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity' on March 13.
Brief Summary: The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Brenipatide
Administered SC.
OTHER: Placebo
Administered SC.
Recruitment Status: NOT_YET_...